(Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. UTI Healthcare Fund is a Equity - Sectoral fund launched on 28 Jun 99. It is a fund with High risk and has given a Below is the key information for UTI Healthcare Fund Returns up to 1 year are on Historical performance (Yearly) on absolute basis UTI Healthcare Fund - G
Scheme Objective
CAGR return of 15% since its launch. Ranked 40 in Sectoral category. Return for 2025 was -3.1% , 2024 was 42.9% and 2023 was 38.2% . NAV as on 7 Jul 26 ₹327.591 ↓ -2.36 (-0.72 %) Net Assets (AUM) as on 31 May 2026 ₹1,217 Cr. Launch Date 28 Jun 1999 Category Equity - Sectoral Rating ☆ Type Open Ended Fund Risk High AMC UTI Asset Management Company Ltd Alpha Ratio 0.91 Expense Ratio 2.26 % Sharpe Ratio 0.419 Information Ratio 0.08 Benchmark Not Available Min Investment ₹5,000 Min SIP Investment ₹500 Exit Load 0-1 Years (1%),1 Years and above(NIL) NAV Price Chart
Returns
Annual Compounded Returns
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 7 Jul 26 Duration Returns 1 Month 6.5% 3 Month 20.8% 6 Month 13.1% 1 Year 12.6% 3 Year 25.6% 5 Year 14.3% 10 Year 15 Year Since launch 15% Historical Annual Returns
Year Returns 2024 -3.1% 2023 42.9% 2022 38.2% 2021 -12.3% 2020 19.1% 2019 67.4% 2018 1.2% 2017 -7.5% 2016 6.2% Growth of 10k Over Years
Date Value 30 Jun 21 ₹10,000 30 Jun 22 ₹8,478 30 Jun 23 ₹10,006 30 Jun 24 ₹14,264 30 Jun 25 ₹17,337 30 Jun 26 ₹19,764 Asset Allocation
Asset Class Value Cash 5.55% Equity 94.45% Sector Allocation
Sector Value Health Care 94.45% Top Securities Holdings / Portfolio
Holdings/Securities
Name Global Industry Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMADrug Manufacturers - Specialty & Generic 9% ₹108 Cr 600,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLABDrug Manufacturers - Specialty & Generic 5% ₹59 Cr 88,814
↑ 28,076 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | AJANTPHARMDrug Manufacturers - Specialty & Generic 5% ₹57 Cr 195,295
↓ -41,216 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLANDDrug Manufacturers - Specialty & Generic 4% ₹48 Cr 215,251 Lupin Ltd (Healthcare)
Equity, Since 28 Feb 25 | LUPINDrug Manufacturers - Specialty & Generic 4% ₹46 Cr 203,834
↓ -6,166 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSPMedical Care Facilities 4% ₹43 Cr 53,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDYDrug Manufacturers - Specialty & Generic 3% ₹38 Cr 290,000 Caplin Point Laboratories Ltd (Healthcare)
Equity, Since 31 Dec 23 | CAPLIPOINTDrug Manufacturers - Specialty & Generic 3% ₹37 Cr 185,000
↑ 39,847 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 May 21 | ALKEMDrug Manufacturers - Specialty & Generic 3% ₹37 Cr 68,000 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | FORTISMedical Care Facilities 3% ₹37 Cr 400,000
Talk to our investment specialistFund Managers
Name Since Tenure Kamal Gada 2 May 22 4.17 Yr. Custodians
Company Address Axis Bank Ltd null Deutsche Bank AG MUMBAI Deitsche bank,Kodak House Stock Holding Corporation of India Mittal Court, ‘B’ Wing,,Nariman Point Registrar & Transfer Agent
KFin Technologies Ltd Address 138 -Suyesh Solitaire, Nr. Podar International School,Kudasan, Gandhinagar, Gujarat FAX N.A Email N.A Administrator Companies
Company Address UTI Asset Management Co Ltd PMS Division, UTI - Tower, “Gn” Block, Bandra Kurla Complex, Mumbai- 400051 Auditors
Company Address S. R. BATLIBOI & Co Express Tower, 6th Floor,Nariman Point,Mumbai All Plan & Options
Fund and Plan NAV 6 Month 1 Year 3 Year 5 Year UTI Healthcare Fund
Growth ₹327.591
↓ -2.36 13.12 % 12.64 % 25.56 % 14.33 % UTI Healthcare Fund
Normal Dividend, Payout ₹253.182
↓ -1.82 13.12 % 12.64 % 25.56 % 14.33 % UTI Healthcare Fund
Normal Dividend, Reinvestment ₹253.182
↓ -1.82 13.12 % 12.64 % 25.56 % 14.33 % Data as on 7 Jul 26